Early-stage venture capital firm W Health Ventures on Thursday announced the initial close of its second fund at nearly $61 million (Rs 550 crore), with a target corpus of Rs 630 crore.
In a statement, the firm said that it will continue to follow its company creation model under Fund II, focusing on building and scaling healthcare companies from the ground up in India and across the US-India corridor.
With Fund II, W Health Ventures plans to build and scale 8-10 new companies over the next four years, with planned investments of Rs 30-50 crore in each venture.
W Health Ventures has begun deploying capital from its second fund. Everhope Oncology, the first company from Fund II, is a national oncology platform founded with Narayana Health to reimagine cancer care in India.
The fund is also exploring opportunities in spaces such as longevity and modern preventive health, geriatrics, and chronic pain management.
“We work with founders, clinicians, operators, and strategic partners to co-found companies from inception. We identify underserved clinical and operational whitespaces, assemble founding teams, and support execution through shared playbooks, partnerships, and an experienced platform team. Our portfolio companies impact over 25 million individuals globally, and we aim to scale this to a billion lives over the next two decades,” said Dr Pankaj Jethwani, Managing Partner at W Health Ventures.
Founded in 2021, W Health Ventures funds healthcare companies addressing critical unmet healthcare needs. The firm’s portfolio from the first fund include Nivaan (chronic pain), BeatO (diabetes), ElevateNow (obesity), BabyMD (paediatrics), and Mylo (parenting) in India, along with cross-border companies like Wysa (AI mental health services) and Reveal HealthTech (AI transformation services). All Fund I companies have raised external growth capital.
In partnership with its venture studio 2070 Health, W Health also builds innovative healthcare companies, including Nivaan Care, from scratch.
